Navigation Links
Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
Date:5/31/2013

SEATTLE, May 31, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive results from its Phase 1 clinical program evaluating OMS824, the lead compound from its phosphodiesterase 10 (PDE10) program. This study measured the extent to which OMS824 binds to PDE10 in the basal ganglia, a region of the brain that has been linked to a wide range of diseases that affect cognition. The results show that the selected dose of OMS824 achieved approximately 50 percent occupancy of PDE10 without triggering the extrapyramidal symptoms (loss of muscle control, e.g., muscle rigidity, tremors, or involuntary muscle movements) reported as side effects with other PDE10 inhibitors that achieved similar or significantly lower occupancy levels. OMS824 is Omeros' proprietary compound that selectively inhibits PDE10, and the Company plans to advance into Phase 2 clinical trials in Huntington's disease and schizophrenia later this year.

The OMS824 Phase 1 clinical program previously evaluated the tolerability and pharmacokinetics of single and multiple doses of OMS824 in healthy subjects. OMS824 was well tolerated by all subjects, and the only apparent drug-related adverse event was mild somnolence at the highest dose evaluated. In the clinical trial reported today, positron emission tomography (PET) scans were used to measure the binding activity of OMS824 to PDE10 in the brains of healthy subjects who received once daily dosing of OMS824 for seven days.  Quantitation of PET images showed that approximately 50 percent occupancy of PDE10 in the basal ganglia was achieved by this dosing regimen. OMS824 was well tolerated and, consistent with earlier studies, mild somnolence was the only apparent adverse effect.

Other PDE10 inhibitors under development have been associated with extrapyramidal symptoms in humans at similar or substanti
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Omeros Announces Discovery in MASP-2 Program
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 PuraMed BioScience ® ... of over-the-counter (OTC) medicinal and healthcare products, announced ... M name along with the name,s red and ... the trademarked name MigraPure ®  going forward. ... PuraMed,s homeopathic, natural migraine pain reliever will be ...
(Date:7/30/2014)... 30, 2014  El Camino Hospital, a leader in ... utilizing the Leaf Patient Monitoring system to help prevent ... of patients susceptible to bed sores. The ... study of the system, which showed dramatic improvement in ... regularly is the one of the most effect ways ...
(Date:7/30/2014)... July 30, 2014  InnoPharma, Inc. today announced the ... generic equivalent of Zyprexa® injection), in Canada.  Olanzapine is ... behaviors in patients with schizophrenia or bipolar I mania. ... drug, InnoPharma has entered into an agreement with Sandoz ... will make, use, sell, market and distribute Olanzapine Injection ...
Breaking Medicine Technology:PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2
... 2011 Reportlinker.com announces that a new market research ... Epidemiology: Lupus http://www.reportlinker.com/p0484924/Epidemiology-Lupus.html ... 404,300 prevalent cases of systemic lupus erythematosus (SLE) in ... cases in women between 45 and 64 years of ...
... /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR ... manufacturing, and marketing of branded generic and proprietary pharmaceuticals ... unaudited financial results for the first quarter ended March ... market opens in the United States. Simcere,s management will ...
Cached Medicine Technology:Reportlinker Adds Epidemiology: Lupus 2Simcere Pharmaceutical Group to Announce First Quarter 2011 Financial Results on Tuesday, May 10, 2011 2
(Date:7/30/2014)... LTC Consumer, an independent, free online service to help ... Instant Quote tool on its website, LTCconsumer.com , announced ... are free and unlimited. , The Instant Quote tool ... including age, gender, and state of residence – and delivers ... to enter any contact information to get started). There is ...
(Date:7/30/2014)... Washington, DC (PRWEB) July 30, 2014 ... its appreciation to U.S. Sens. Thad Cochran (R-MS) ... push for improvements in telemedicine coverage under Medicare, ... Cochran and Wicker, both Mississippi Republicans, introduced the ... bill to a House version, H.R. 3306, introduced ...
(Date:7/30/2014)... 2014 Hospitals continually face the ... care that their practitioners provide. During a recent ... discussed the importance of establishing effective peer review ... and quality of care. , With regard ... Rowe elaborated on setting performance expectations, conducting regular ...
(Date:7/30/2014)... Bay Aquarium Research Institute (MBARI) have observed a deep-sea ... yearslonger than any other known animal. Throughout this time, ... from predators. This amazing feat represents an evolutionary balancing ... having plenty of time to develop within their eggs, ... little or no food. , Every few months for ...
(Date:7/30/2014)... 30, 2014 Frozen shoulder (Adhesive capsulitis) affects ... to develop this nasty condition which occurs most frequently in ... last up to two and half years if not treated. ... and with good reason: it can render your shoulder so ... is, if you aren't in too much pain to get ...
Breaking Medicine News(10 mins):Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2Health News:ATA Applauds Senators’ Push for Federal Telemedicine Improvements 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 3Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 2Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4
... ANGELES, Oct. 16 D.I.S.C. (Diagnostic and,Interventional Spinal and ... "Official Medical Center" of the N.H.L.,s Los,Angeles Kings hockey ... into the sports marketing arena in a very significant,way. ... natural fit for us and we,are thrilled to be ...
... Surgical,Company (Nasdaq: STAA ) today announced that ... ended September 29, 2007 on Tuesday, October,30, 2007 ... a conference call,and webcast on Tuesday, October 30, ... Company,s third quarter and current corporate developments. The,dial-in ...
... American,Cancer Society (ACS) inaugurated the National Breast Cancer ... Mammography Day. The NBCAM,was conceived and funded by ... petrochemicals, and its U.S. subsidiary,Zeneca Pharmaceuticals. Zeneca is ... of breast cancer, even though it is toxic ...
... While it is commonly thought that men with low ... or sexual deviance, new research has found the men ... sex education previously taken. , A team of ... and without an intellectual disability and a history of ...
... Oct. 16 Expected to be,her family,s Halloween treat, ... 1 pound, 10 ounces. Today, the five-year-old of,Allentown, Pennsylvania ... Catharine, who was born 16 weeks early, measuring only ... than half a million,babies born preterm each year in ...
... More Than,100,000 Kids, WASHINGTON, Oct. 16 As ... that would increase the,state cigarette tax to fund children,s ... increase would not only fund health care for more,than ... and,tobacco-related health care costs and save thousands of lives., ...
Cached Medicine News:Health News:D.I.S.C. Scores First Sponsorship Deal as Official Medical Center of the Los Angeles Kings 2Health News:STAAR Surgical Announces Third Quarter 2007 Earnings Release Date and Conference Call 2Health News:Cancer Prevention Coalition: The Breast Cancer Awareness Month Misleads Women 2Health News:Cancer Prevention Coalition: The Breast Cancer Awareness Month Misleads Women 3Health News:'Corrective' sex education may make sexual offenders more dangerous 2Health News:March of Dimes Selects Pennsylvania Girl as 2008 National Ambassador 2Health News:New Report: Increasing Oregon's Cigarette Tax Will Reduce Smoking, Save Lives and Save Money 2
AST (SGOT) R1 + R2. Automated analyzer test kits....
For the quantitative determination of aspartate aminotransferase (AST) in human serum. The reagents are used in routine examination and monitoring of therapy and relapses....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 440 U/L at 30C. Single vial, dry powder reagen...
Medicine Products: